ServicenavigationHauptnavigationTrailKarteikarten


Research unit
EU RFP
Project number
95.0695
Project title
Development of gene therapy strategies for neurological diseases

Texts for this project

 GermanFrenchItalianEnglish
Key words
-
Anzeigen
-
-
Alternative project number
-
-
-
Anzeigen
Research programs
-
-
-
Anzeigen
Short description
-
Anzeigen
-
-
Partners and International Organizations
-
Anzeigen
-
-
Abstract
-
Anzeigen
-
-
References in databases
-
-
-
Anzeigen

Inserted texts


CategoryText
Key words
(French)
Gene therapy; neurotrophic factors; parkinson's disease
Alternative project number
(English)
EU project number: BMH4CT961012
Research programs
(English)
EU-programme: 4. Frame Research Programme - 4.2 Agriculture and agroindustry
Short description
(French)
Veuillez consulter l'abstract
Partners and International Organizations
(French)
CNRS-LGN (FRANCE), Univ. of Lund (SWEDEN), CEA (FRANCE)
Abstract
(French)
To determine if neurturin (NTN), a homolog of glial cell line-derived neurotrophic factor (GDNF), is able to preserve tyrosine hydroxylase immunoreactivity (TH-IR) in a rat model of Parkinson's disease (PD), polymer encapsulated cells genetically engineered to release NTN were implanted near the substantia nigra before a unilateral medial forebrain bundle axotomy. One week later, animals that had received a NTN capsule had a significantly higher percentage of TH-IR cells (51.4%) than animals that had received a capsule containing non-transfected parent cells (16.2% compared to the control side). These results suggest that NTN, like GDNF, might be of therapeutic value for the treatment of PD [Neurturin protects dopaminergic neurons following medial forebrain bundle axotomy; JL Tseng, SL Bruhn, AD Zurn, P Aebischer, NeuroReport 9: 1817-1822 (1998)].
Besides ex vivo gene therapy using encapsulated genetically engineered cells, in vivo gene therapy via recombinant viruses can also be used for the localized delivery of neurotrophic factors in the brain. A retroviral vector derived from lentiviruses has been developped as a gene transfer system. Unlike other retroviruses, it is capable of integrating genetic material into the chromosome of postmitotic cells and does not encode viral proteins. We have used this lentiviral vector for the localized delivery of GDNF in a rat model of PD. Following a single injection in the substantia nigra of adult rats with a vector expressing GDNF, 56% of the nigral dopaminergic neurons remained following medial forebrain bundle axotomy, compared to 24% in animals transduced with a control reporter gene. Lentiviral vectors could thus be useful tools as vectors for the local delivery of bioactive molecules into defined structures of the central nervous system (Self-inactivating lentiviral vectors with enhanced transgene expression as a potential gene transfer system for Parkinson's disease; N. Déglon, JL Tseng, JC Bensadoun, AD Zurn, Y Arsenijevic, L Pereira de Almeida, R Zufferey, D Trono, P Aebischer, submitted for publication).

References in databases
(English)
Swiss Database: Euro-DB of the
State Secretariat for Education and Research
Hallwylstrasse 4
CH-3003 Berne, Switzerland
Tel. +41 31 322 74 82
Swiss Project-Number: 95.0695